Amy Well
SVP, Chubb Group; Chief Marketing and Communications OfficerChubb
CMOView Profile →Head of Global Product Development and Chief Medical Officer · Roche Group
Levi Garraway is Roche’s head of Global Product Development and chief medical officer. His earlier career combined clinical oncology, cancer-genomics research, biotechnology company formation and oncology development leadership at Eli Lilly.
Last reviewed: Nov 10, 2026
Head of Global Product Development and Chief Medical Officer
Roche Group
Last Reviewed: November 10, 2026
Levi Garraway is Roche’s head of Global Product Development and chief medical officer. His earlier career combined clinical oncology, cancer-genomics research, biotechnology company formation and oncology development leadership at Eli Lilly.
Joined Roche and Genentech in October 2019 to lead Global Product Development and serve as chief medical officer.
Built an academic cancer-research career at Dana-Farber, Harvard and the Broad Institute.
Co-founded Foundation Medicine and Tango Therapeutics.
After completing his MD and PhD in 1999, Garraway undertook internal-medicine internship and residency at Massachusetts General Hospital. He pursued medical-oncology fellowship training at Dana-Farber and served as a chief resident at Massachusetts General in 2003. His subsequent research fellowship was in William Sellers’s laboratory at Dana-Farber.
He became an instructor at Dana-Farber and Harvard Medical School in 2005, assistant professor of medicine in 2007 and associate professor in 2011. His research career also included membership of the Broad Institute and work as a Howard Hughes Medical Institute investigator.
Alongside academic research, he co-founded Foundation Medicine in 2010 and worked with the company as a consultant through 2016. He also co-founded Tango Therapeutics in 2017. These activities accompanied his work in cancer genomics and resistance to targeted therapies.
Lilly announced his recruitment in September 2016, with his appointment as senior vice president for Global Development and Medical Affairs in Oncology effective January 1, 2017. In 2018, he became senior vice president for Oncology R&D and Novel Target Research.
Garraway joined Roche and Genentech in October 2019 as executive vice president, head of Global Product Development and chief medical officer. He joined Genentech’s board in August 2020 and became a member of Roche’s enlarged Corporate Executive Committee in 2023. His subsequent institutional service includes Dana-Farber’s board of trustees from 2023.
Garraway earned an AB in biochemical sciences at Harvard College in 1990. He received his MD and PhD in biochemistry and molecular pharmacology from Harvard Medical School in 1999.